Royalty Pharma plc (RPRX) FY2024 YTD Q3 P&L / Income Statement

Royalty Pharma plc (RPRX) FY2024 YTD Q3 P&L / Income Statement

Income statement for 2024-01-01 through 2024-09-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total income and other revenues

1,669,935,000 US dollars

Total operating (income)/expense, net

739,005,000 US dollars

Operating income

930,930,000 US dollars

Total other (income)/expense, net

65,532,000 US dollars

Consolidated net income before tax

996,462,000 US dollars

Income tax expense

0 US dollars

Consolidated net income

996,462,000 US dollars

Income from financial royalty assets

1,587,577,000 US dollars

Other royalty income and revenues

82,358,000 US dollars

Research and development funding expense

1,500,000 US dollars

Provision for changes in expected cash flows from financial royalty assets

568,425,000 US dollars

General and administrative expenses

169,080,000 US dollars

Chart connections

• Revenue minus operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
• Of which attributable to Royalty Pharma plc: $650.77 M; to noncontrolling interests: $345.69 M.